Compare Globus Medical Inc. Class A Common Stock (GMED) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

VNQI trades at $42.04, up 0.14% on the day, but technical indicators signal a bearish trend with moving averages and overall signals pointing lower. The ETF focuses on international real estate outside the U.S., offering diversification across more than 30 countries and a competitive expense ratio of 0.12%. Recent news highlights a significant drop in short interest in September 2026, suggesting reduced bearish speculation, while comparisons with peers emphasize its higher dividend yield.

The outlook remains cautious due to global real estate market volatility and bearish technicals, though reduced short interest and international exposure present opportunities for yield-seeking investors. Risks include currency fluctuations and economic downturns in foreign markets, requiring careful monitoring of macroeconomic trends for potential recovery.